Urinary neutrophil gelatinase-associated lipocalin-guided risk assessment for major adverse kidney events after open-heart surgery
Christian Albert, Annemarie Albert, Rinaldo Bellomo, Siegfried Kropf, Prasad Devarajan, Sabine Westphal, Hassina Baraki, Ingo Kutschka, Christian Butter, Michael Haase, Anja Haase-Fielitz
Biomarkers in Medicine | FUTURE MEDICINE LTD | Published : 2018
Awarded by NIH
This study was supported by grants from the German Heart Foundation (Deutsche Stiftung fur Herzforschung) and from the Else Kroner-Fresenius-Stiftung, Germany. P Deverajan is supported by NIH grant P50 DK096418. C Albert has received honoraria speaking for Siemens Healthcare Diagnostics. R Bellano has acted as paid consultant to Abbott Diagnostics and Biosite Inc. P Devarajan has licensing agreements for developing the use of NGAL as a biomarker of kidney injury with Abbott Diagnostics and BioPorto Inc. M Haase has received honoraria speaking for Abbott Diagnostics, Alere and Biosite Inc. Companies are involved in the development of NGAL assays to be applied in clinical practice. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.